Winfield Associates Inc. Invests $482,000 in Illumina, Inc. (ILMN)

Winfield Associates Inc. acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,550 shares of the life sciences company’s stock, valued at approximately $482,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Massmutual Trust Co. FSB ADV lifted its stake in Illumina by 83.0% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 39 shares during the last quarter. Proficio Capital Partners LLC lifted its stake in shares of Illumina by 61.7% during the 4th quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Lake Point Wealth Management acquired a new stake in shares of Illumina during the 4th quarter worth about $30,000. Moody National Bank Trust Division acquired a new stake in shares of Illumina during the 4th quarter worth about $31,000. Finally, Virtus ETF Advisers LLC acquired a new stake in shares of Illumina during the 4th quarter worth about $31,000. Institutional investors and hedge funds own 90.80% of the company’s stock.

A number of analysts have recently issued reports on ILMN shares. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a research note on Wednesday, February 13th. Deutsche Bank cut shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price for the company. in a research note on Friday, January 25th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $355.00 target price for the company in a research note on Tuesday, April 2nd. Bank of America reiterated a “buy” rating and issued a $355.00 price objective on shares of Illumina in a research note on Wednesday, January 30th. Finally, Leerink Swann upgraded shares of Illumina to an “outperform” rating and dropped their price objective for the stock from $380.00 to $365.00 in a research note on Wednesday, January 30th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $353.58.

ILMN stock opened at $317.37 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66. Illumina, Inc. has a 12 month low of $261.61 and a 12 month high of $372.61. The stock has a market capitalization of $46.65 billion, a price-to-earnings ratio of 55.48, a PEG ratio of 2.27 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.34 by $0.26. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The firm had revenue of $846.00 million for the quarter, compared to analyst estimates of $838.70 million. During the same period last year, the firm earned $1.45 EPS. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. Equities research analysts forecast that Illumina, Inc. will post 6.68 earnings per share for the current fiscal year.

In other Illumina news, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $321.96, for a total value of $1,062,468.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Omead Ostadan sold 1,260 shares of the firm’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $294.62, for a total transaction of $371,221.20. Following the completion of the transaction, the senior vice president now directly owns 29,534 shares in the company, valued at $8,701,307.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,826 shares of company stock worth $12,022,575. Insiders own 0.38% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/winfield-associates-inc-invests-482000-in-illumina-inc-ilmn.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Further Reading: How to calculate the annual rate of depreciation

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.